M&A Deal Summary |
|
|---|---|
| Date | 2022-04-13 |
| Target | Sierra Oncology |
| Sector | Healthcare Services |
| Buyer(s) | GlaxoSmithKline |
| Sellers(s) | Vivo Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.9B GBP |
| Advisor(s) | Lazard Ltd. (Financial) Wilson Sonsini Goodrich & Rosati (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 94,066 |
| Revenue | 34.1B GBP (2020) |
GlaxoSmithKline is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GlaxoSmithKline was founded in 1715 and is based in Brentford, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 28 of 31 |
| Sector (Healthcare Services) | 2 of 2 |
| Type (Add-on Acquisition) | 20 of 23 |
| State (California) | 4 of 5 |
| Country (United States) | 16 of 18 |
| Year (2022) | 1 of 2 |
| Size (of disclosed) | 4 of 27 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-11 |
GSK - Cephalosporin Antibiotics Business
Brentford, United Kingdom GSK's Cephalosporin Antibiotics Business is a provider of antibiotics used to treat a range of bacterial infections. |
Sell | $500M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-31 |
Affinivax
Cambridge, Massachusetts, United States Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines, using its patented biotin-rhizavidin binding approach to optimize the body’s protective immune response to address infectious and other immune-mediated diseases. Affinivax is based in Cambridge, Massachusetts. |
Buy | $2.1B |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 6.4B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 12 |
| Sector (Healthcare Services) | 1 of 1 |
| Type (Add-on Acquisition) | 3 of 3 |
| State (California) | 6 of 6 |
| Country (United States) | 11 of 11 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-22 |
Impel NeuroPharma
Seattle, Washington, United States Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. Impel NeuroPharma was formed in 2008 and is based in Seattle, Washington. |
Sell | - |
